The latest results from Genentech’s proposed eye disease treatments are demonstrating strong potential to help reduce treatment frequencies and deliver improved outcomes.
AbbVie is partnering with biotechnology firm REGENXBIO to develop and commercialize a new drug that could treat a wide range of eye diseases, including wet age-related macular degeneration (wet AMD).
Pivoting from conflicting and controversial press over the company’s approved Alzheimer’s disease treatment, Biogen announced that its gene therapy drug timrepigene emparvovec failed to show a clinically meaningful benefit for a rare inherited eye disease in a Phase III trial.
Novartis cut three Phase III trials of the eye therapy Beovu (brolucizumab) after the studies showed higher rates of intraocular inflammation with frequent dosing intervals of the therapy.
AbCellera and Kodiak Sciences announced a new partnership to create and develop therapeutic antibodies for ophthalmologic indications.
Harbour BioMed closed a $102 million Series C funding round that will be used to advance the company’s oncology and immunology portfolio.
Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.
Swiss drugmakers Roche and Novartis underscored how their portfolios are increasingly clashing on the commercial battlefield, announcing new data on drugs aimed at capturing market share from each other.
Paris-based GenSight Biologics reported the first group of data from Week 96 of the company’s RESCUE Phase III clinical trial.
Gyroscope Therapeutics – with headquarters in Stevenage, UK – is merging with Ambler, Pennsylvania-based Orbit Biomedical. The companies will operate under the Gyroscope name and focus on gene therapies for diseases of the eye.